Table 1. Baseline characteristics of the patients.
| CHB (n = 91) | CHC (n = 108) | Control (n = 23) | |
|---|---|---|---|
| Age (years old) | 41.0 ± 10.4* | 54.8 ± 11.2** | 38.5 ± 10.3 |
| Gender (male/female) | 66/25*,** | 49/59 | 11/12 |
| AST (IU/L) | 83.8 ± 88.0* | 63.7 ± 41.6 | N.D. |
| ALT (IU/L) | 139.6 ± 168.1*,** | 75.7 ± 58.7** | 10.8 ± 4.3 |
| Platelets (x 103/mL) | 181.4 ± 63.7 | 170.2 ± 65.4 | N.D. |
| HBV DNA (Log copies/mL) | 6.0 ± 2.2 | N.A. | N.A. |
| HBeAg (positive/negative) | 71/20 | N.A. | N.A. |
| HCV genotypes (1/2) | N.A. | 71/37 | N.A. |
| HCV RNA (L/H) | N.A. | 6/103 | N.A. |
| APRI | 1.53 ± 1.62 | 1.32 ± 1.13 | N.D. |
| FIB-4 | 2.01 ± 2.03* | 2.96 ± 2.07 | N.D. |
| Liver fibrosis (F1/F2/F3/F4) | 39/22/20/10 | 46/26/19/17 | N.D. |
| Inflammatory activity (A1/A2/A3) | 33/43/15 | 41/55/12 | N.D. |
| MiR-122 level (fold) | 260.5 ± 551.1*,** | 12.2 ± 25.9 | 3.70 ± 8.13 |
| WFA(+)-M2BP level (C.O.I.) | 1.26 ± 1.55*,** | 2.84 ± 3.03** | 0.44 ± 0.19 |
Data are presented as the mean ± standard deviation.
* p<0.05 vs CHC group;
** p<0.05 vs Control group;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; FIB-4, Fibrosis 4; HCV RNA L, < 100 KIU/mL; HCV RNA H, ≥ 100 KIU/mL; N.A., not applicable; N.D., not done; CHB, chronic hepatitis B; CHC, chronic hepatitis C; Control, control subjects.